

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-77 (cancelled).

78. (previously presented) A compound of the general formula

R-NH-HAEGTFTSDVSSYLEGQAAKEFLAVLK-CONH₂ (SEQ ID NO:1)

wherein R = H or an organic compound having from 1-10 carbon atoms.

79. (previously presented) The compound according to claim 78, wherein R is a carboxylic acid moiety.

80. (previously presented) The compound according to claim 79, wherein R is formyl-, acetyl-, propionyl-, isopropionyl-, methyl-, ethyl-, propyl-, isopropyl-, n-butyl-, sec-butyl-, or tert-butyl-.

81. (previously presented) The compound according to claim 78, wherein the compound exists in a phosphorylated, acetylated, and/or glycosylated form.

82. (currently amended) A method of using a pharmaceutical composition containing a compound according to claim 78, comprising administering the composition to a person for the treatment of ~~insulin-dependent~~ insulin-independent diabetes mellitus.
83. (previously presented) The method according to claim 82, wherein the composition is administered in a long-lasting or pulsatile manner.
84. (previously presented) The method according to claim 82, wherein the composition is administered subcutaneously, intravenously, perorally, intramuscularly, or transpulmonarily.
85. (previously presented) A composition for human administration comprising the compound according to claim 78, in combination with a physiologically acceptable carrier or diluent.
86. (previously presented) The composition according to claim 85, in a release form by which the release of the compound is attained in a long-lasting or pulsatile manner.
87. (previously presented) The composition according to claim 85, suitable for subcutaneous, intravenous, or intramuscular administration.

88. (previously presented) The composition according to claim 85, suitable for peroral administration.
89. (previously presented) The composition according to claim 85, suitable for transpulmonary administration.
90. (previously presented) A composition comprising a therapeutically effective amount of the compound according to claim 79, in combination with a pharmaceutically acceptable carrier or diluent.
91. (previously presented) The composition according to claim 90, in a release form by which release of the compound is attained in a long-lasting or pulsatile manner.
92. (previously presented) The composition according to claim 90, suitable for subcutaneous, intravenous, or intramuscular administration.
93. (previously presented) The composition according to claim 90, suitable for peroral administration.

94. (previously presented) The composition according to claim 90, suitable for transpulmonary administration.